Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Mitrade Enters Bloomberg.com Partnership as MENA’s Rapidly Shifting Outlook Makes Financial Context Imperative

    July 30, 2026

    Apple market cap reaches 4.94 trillion to top Nvidia

    July 29, 2026

    Gold prices fall on strong dollar ahead of central bank meeting

    July 29, 2026
    Facebook X (Twitter) Instagram
    Maghreb DailyMaghreb Daily
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Maghreb DailyMaghreb Daily
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    XERF arrives in Dubai as Biolite Clinic leads Middle East launch

    July 23, 2026

    ART Elite Car Rental Announces Its Fleet Expansion with 300+ Jetour Vehicles

    June 26, 2026

    SPIEF 2026 Energy Panel Highlights Global Economic Transformation

    June 8, 2026
    Latest News

    Apple market cap reaches 4.94 trillion to top Nvidia

    Technology July 29, 2026

    The valuation shift reflects broader recalibrations across international financial markets as institutional managers re-evaluate capital commitments tied to artificial intelligence infrastructure. While competing hyperscale computing enterprises including Alphabet and Tesla accelerated capital investments toward data centers, robotics, and autonomous transport networks, Apple maintained disciplined expenditure controls over consecutive fiscal quarters. Market participants increasingly view Apple’s disciplined spending approach as a operational buffer, allowing the firm to expand its proprietary Apple Intelligence software ecosystem without incurring high infrastructure depreciation costs. Trading patterns across major equity benchmarks highlighted diverging sentiment between hardware component suppliers and consumer technology platforms. Nvidia shares experienced increased selling pressure alongside wider pullbacks across semiconductor equities, as investors scrutinized the timeline for financial returns on massive artificial intelligence data center investments. The Philadelphia Semiconductor Index recorded notable weekly declines as market participants reassessed elevated valuation multiples across pure-play chipmakers. Despite persistent demand for graphics processing units, concerns surrounding energy supply constraints, macroeconomic interest rate trajectories, and capital expenditure intensity weighed on semiconductor equity prices.

    Gold prices fall on strong dollar ahead of central bank meeting

    July 29, 2026

    Porsche to cut 5000 more jobs under restructuring plan

    July 28, 2026

    Senate crypto bill faces pushback over conflict of interest rules

    July 28, 2026

    May foreign tourist arrivals drive South Korea travel surplus

    July 27, 2026

    Extreme heat wave triggers emergency alerts across Daegu

    July 27, 2026

    Heat intensifies severe drought across European nations

    July 24, 2026

    Amazon wildfires in Brazil fall to lowest level in four decades

    July 23, 2026
    © 2026 Maghreb Daily | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.